Market noise is relentless. Financial headlines scream about the same handful of stocks while important opportunities—the kind that can meaningfully impact your portfolio—often fly completely under the radar.
That’s exactly why we publish this watchlist each week.
This week provided a stark reminder of how quickly market sentiment can shift. The S&P 500 suffered its first negative week in ten as losses accelerated, with the Nasdaq Composite tumbling 4.7% and semiconductor stocks facing a bloodbath not seen since March 2020. The iShares Semiconductor ETF plunged 10% with Broadcom down 8%, Marvell Technology down 16%, Intel and AMD down 11% each, and Micron Technology down 13%—as investors positioned for the massive SpaceX IPO arriving next week at a valuation of $1.77 trillion.
The portfolio rebalancing is real and the opportunity is genuine. While everyone panics about technology valuations, profit-taking, and positioning for the largest IPO ever, a different dynamic is unfolding beneath the chaos. The 10-year Treasury yield jumping above 4.5% and the 30-year above 5% has triggered defensive rotation into healthcare and staples—exactly where savvy investors should be hunting for opportunities. Some companies are thriving amid volatility while others are oversold due to sector correlation rather than fundamental deterioration.
While most investors are distracted by headlines of tech carnage and cryptocurrency collapse, we’re digging through the volatility to identify companies at genuine inflection points—both those gaining from portfolio rotation and those positioned to capitalize on infrastructure buildout that continues regardless of near-term sentiment. Our focus isn’t on what’s already priced in, but rather on what the market hasn’t fully appreciated yet.
Each week, we spotlight three stocks that merit your attention. We focus on opportunities where timing, valuation, and catalysts align to create potentially favorable entry points.
Our rigorous analysis goes beyond surface-level metrics to identify opportunities that most retail investors don’t have time to uncover. Each pick comes with clear reasoning, specific triggers to watch for, and a compelling risk-adjusted profile designed to help you make more informed investment decisions.
Here’s what we’re watching this week:
Credo Technology (CRDO) — AI Infrastructure “Purple Cables” Oversold in Semiconductor Carnage
Credo Technology presents an exceptional opportunity as the company making proprietary Active Electrical Cables—known internally as “purple cables”—connecting graphics processing units inside AI data center clusters trades down 4.6% on Friday amid broader semiconductor destruction, creating entry point into foundational AI infrastructure that continues regardless of chip sector sentiment. Trading around $208 per share despite being up more than 100% from early April prices, the company has become embedded in hyperscaler operations as the critical link solving physics problems that emerge when AI clusters scale to hundreds of thousands of GPUs running in parallel.
The investment thesis centers on Credo’s positioning in infrastructure that becomes more critical as AI clusters densify. As AI clusters scale to massive proportions, the connections between GPUs become a chokepoint—and Credo’s Active Electrical Cables handle that connection at lower power consumption and higher reliability than alternatives. This creates simple physics-based demand: as data center density increases, demand for superior interconnect solutions accelerates, making Credo’s technology essential infrastructure rather than optional component.
The customer validation proves exceptional as Credo has confirmed Microsoft, Amazon, and xAI as customers with each representing significant revenue share, plus a fourth hyperscaler ramping toward the 10% revenue threshold heading into fiscal 2026. When the largest technology companies on earth are buying cables in bulk and asking for more, that’s an embedded infrastructure position with switching costs making displacement difficult despite customer concentration risks. The competitive moat stems from design wins with every major optical module manufacturer and proprietary signal integrity expertise that cannot be easily replicated.
The board’s recent conviction provides crucial validation as Credo’s CEO received a performance stock award with revenue milestones spanning $2.5 billion to $7.5 billion and stock price hurdles of $244.70 to $489.40 vesting through 2031. This represents the board literally locking the CEO to a specific growth trajectory they genuinely believe in—an extraordinarily bullish signal that leadership is betting their compensation on exceptional expansion.
The semiconductor sector selloff creating near-term pressure on Credo appears driven by portfolio rotation and profit-taking rather than fundamental deterioration. While the company faces customer concentration risks and potential architecture changes that could disrupt the business, the head start in design wins and proprietary know-how make displacement harder than it appears on paper. The $100 million year-to-date run-up already priced in much of the bull case, but the near-term volatility selling creates opportunity for patient investors recognizing that AI infrastructure buildout continues regardless of semiconductor sector sentiment.
For growth investors seeking AI infrastructure exposure beyond chips and foundries, Credo Technology’s combination of proprietary position in critical hyperscaler interconnect solutions, confirmed customer adoption from Microsoft, Amazon, and xAI, board-level conviction through CEO performance awards vesting to $489+ stock price target by 2031, design wins at every major optical module manufacturer creating competitive moat, $2.5-7.5B revenue trajectory through 2031, and near-term sector selloff creating entry opportunity after 100% appreciation makes this AI infrastructure play a compelling long-term holding for patient investors understanding that the wires and optical connections powering AI buildout create just as much value as the chips themselves.
MercadoLibre (MELI) — Latin America E-Commerce Leader With Growth Intact Despite Profitability Dip
MercadoLibre presents an exceptional opportunity as the Latin American e-commerce and fintech leader trades down 19% year-to-date despite reporting startup-like growth rates and despite 85% of covering Wall Street analysts rating the stock a buy with zero sell ratings. Trading around $1,608 per share with an $82 billion market capitalization, the sell-off reflects near-term profitability pressure from strategic investments and credit business challenges—temporary headwinds that management has navigated successfully before and that position the company for accelerating returns.
The investment thesis acknowledges the near-term profitability pressure while recognizing it as a positive rather than negative indicator. Operating income fell from $763 million to $611 million year-over-year while operating margin compressed from 12.9% to 6.9%—causing investor disappointment despite revenue growing 46% year-over-year. The two primary drivers of margin compression are exactly what investors should want: first, strategic investments in the business laying groundwork for future growth; second, pressure on the credit business from new customers, which represents expansion into higher-growth customer segments currently requiring more risk management.
The growth profile demonstrates why patient investors should view the dip as opportunity. Q1 2026 revenue increased 46% currency neutral while gross merchandise volume surged 36% and total payment volume jumped 55%—growth rates typically associated with early-stage startups rather than multi-decade established platforms. MercadoLibre operates in 18 countries where it’s the e-commerce leader while maintaining major fintech positioning, creating diversified revenue streams with compounding network effects.
The profitability pressure should prove temporary as the company has been in similar situations before and managed through successfully. MercadoLibre is already profitable and established as an operating powerhouse—differentiating it from speculative growth companies burning cash with no clear path to profitability. The margin compression reflects strategic prioritization of growth investments and credit expansion rather than fundamental business deterioration, with management confidence demonstrated by continued growth initiatives despite near-term profit pressure.
Wall Street’s overwhelming confidence appears justified as 85% of 26 covering analysts rate the stock a buy with 15% holds and zero sells—suggesting institutional conviction that current pullback represents genuine opportunity rather than deteriorating fundamentals. The 19% year-to-date decline appears driven by growth-at-any-cost investors rotating into defensive sectors during this week’s volatility, creating value for investors maintaining longer time horizons and recognizing the temporary nature of margin pressure from growth investments.
For growth investors seeking Latin American e-commerce and fintech exposure, MercadoLibre’s combination of 46% revenue growth in Q1 2026, 36% gross merchandise volume growth and 55% payment volume growth demonstrating platform acceleration, leadership position across 18 countries with major fintech presence, temporary margin compression from strategic growth investments and credit business expansion, management track record navigating similar periods successfully, 85% Wall Street buy ratings with zero sells, profitable operations supporting margin expansion once growth investments bear fruit, and 19% decline creating entry opportunity for patient investors creates compelling risk-adjusted opportunity in a compounding platform leader at attractive entry point.
Johnson & Johnson (JNJ) — Healthcare Defensive Leader Benefiting From Sector Rotation
Johnson & Johnson represents a foundational opportunity as healthcare stocks benefit from this week’s rotation away from overextended technology valuations while the diversified healthcare company provides defensive positioning through multiple recessions and market dislocations. Trading with modest gains following Friday’s portfolio rebalancing as investors rotated from semiconductor destruction into stability, the healthcare leader offers essential products and services that maintain demand regardless of economic conditions while benefiting from secular tailwinds in aging populations requiring medical care and innovation.
The investment thesis centers on healthcare’s counter-cyclical characteristics during periods of technology volatility and valuation pressure. While semiconductor stocks suffer from compressed multiples and profit-taking, healthcare maintains appeal across economic cycles through its portfolio of pharmaceuticals, medical devices, diagnostics, and consumer health products addressing non-discretionary healthcare needs. The sector rotation visible in this week’s trading—with healthcare stocks gaining while semis collapsed—suggests institutional recognition that growth at reasonable prices remains available in healthcare rather than stretched technology multiples.
Johnson & Johnson’s diversified business model spanning pharmaceuticals, medical devices, consumer health, and innovative emerging medicines provides multiple growth vectors independent of single-market dynamics. The company’s track record through recessions, geopolitical conflicts, and market disruptions demonstrates resilience through its focus on essential healthcare products that patients and providers require regardless of economic conditions. The aging global population creates secular demand growth for J&J’s portfolio as healthcare spending accelerates and treatment options expand.
The defensive positioning proves particularly valuable during periods like this week when growth investors face pressure to rebalance toward quality. Healthcare’s relative stability and predictable cash flows support dividend payments and shareholder returns even as earnings growth moderates, providing foundational portfolio holdings for investors prioritizing capital preservation amid near-term volatility. The sector’s neutral positioning—neither speculative nor completely commodity-like—creates appeal across market conditions.
For defensive investors seeking stability during periods of technology volatility and sector rotation, Johnson & Johnson’s combination of portfolio rebalancing into healthcare visible in this week’s trading, essential products and services maintaining demand across economic cycles, diversified business model spanning pharmaceuticals, devices, and consumer health, secular tailwind from aging populations requiring medical innovation and treatment, track record of resilience through multiple recessions and market disruptions, and positioning to benefit from continued sector rotation from compressed-valuation technology into healthcare stability creates compelling foundational holding for portfolios seeking counter-cyclical positioning during periods of growth-stock volatility and valuation compression.
